Page 2117 - Williams Hematology ( PDFDrive )

2092 Part XII: Hemostasis and Thrombosis Chapter 121: Acquired Qualitative Platelet Disorders 2093

330. Sultan Y, Caen JP: Platelet dysfunction in preleukemic states and in various types of 362. McGrath KM, Stuart JJ, Richards F 2nd: Correlation between serum IgG, platelet mem-
leukemia. Ann N Y Acad Sci 201:300–306, 1972. brane IgG, and platelet function in hypergammaglobulinaemic states. Br J Haematol
331. Cowan DH, Haut MJ: Platelet function in acute leukemia. J Lab Clin Med 79(6):893– 42(4):585–591, 1979.
905, 1972. 363. Kasturi J, Saraya AK: Platelet functions in dysproteinaemia. Acta Haematol 59(2):104–
332. Cowan DH, Graham RC Jr, Baunach D: The platelet defect in leukemia. Platelet 113, 1978.
ultrastructure, adenine nucleotide metabolism, and the release reaction. J Clin Invest 364. Vigliano EM, Horowitz HI: Bleeding syndrome in a patient with IgA myeloma: Interac-
56(1):188–200, 1975. tion of protein and connective tissue. Blood 29(6):823–836, 1967.
333. Foss B, Bruserud O: Platelet functions and clinical effects in acute myelogenous leuke- 365. Shinagawa A, Kojima H, Berndt MC, et al: Characterization of a myeloma patient with
mia. Thromb Haemost 99(1):27–37, 2008. a life-threatening hemorrhagic diathesis: Presence of a lambda dimer protein inhibiting
334. Leinoe EB, Hoffmann MH, Kjaersgaard E, et al: Prediction of haemorrhage in the early shear-induced platelet aggregation by binding to the A1 domain of von Willebrand
stage of acute myeloid leukaemia by flow cytometric analysis of platelet function. Br J factor. Thromb Haemost 93(5):889–896, 2005.
Haematol 128(4):526–532, 2005. 366. DiMinno G, Coraggio F, Cerbone AM, et al: A myeloma paraprotein with specificity
335. Glembotsky AC, Bluteau D, Espasandin YR, et al: Mechanisms underlying platelet for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder. J Clin Invest
function defect in a pedigree with familial platelet disorder with a predisposition to 77:157–164, 1986.
acute myelogenous leukemia: Potential role for candidate RUNX1 targets. J Thromb 367. Mannucci PM, Lombardi R, Bader R, et al: Studies of the pathophysiology of acquired
Haemost 12(5):761–772, 2014. von Willebrand’s disease in seven patients with lymphoproliferative disorders or benign
336. Kaur G, Jalagadugula G, Mao G, Rao AK: RUNX1/core binding factor A2 regulates monoclonal gammopathies. Blood 64(3):614–621, 1984.
platelet 12-lipoxygenase gene (ALOX12): Studies in human RUNX1 haplodeficiency. 368. Takahashi H, Nagayama R, Tanabe Y, et al: DDAVP in acquired von Willebrand syn-
Blood 115(15):3128–3135, 2010. drome associated with multiple myeloma. Am J Hematol 22(4):421–429, 1986.
337. Quintas-Cardama A, Han X, Kantarjian H, Cortes J: Tyrosine kinase inhibitor-induced 369. Lamboley V, Zabraniecki L, Sie P, et al: Myeloma and monoclonal gammopathy of
platelet dysfunction in patients with chronic myeloid leukemia. Blood 114(2):261–263, uncertain significance associated with acquired von Willebrand’s syndrome. Seven new
2009. cases with a literature review. Joint Bone Spine 69(1):62–67, 2002.
338. Neelakantan P, Marin D, Laffan M, et al: Platelet dysfunction associated with ponatinib, 370. Federici AB: Acquired von Willebrand syndrome: Is it an extremely rare disorder or do
a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to we see only the tip of the iceberg? J Thromb Haemost 6(4):565–568, 2008.
multiple tyrosine kinase inhibitor therapy. Haematologica 97(9):1444, 2012. 371. Voisin S, Hamidou M, Lefrancois A, et al: Acquired von Willebrand syndrome asso-
339. Meschengieser S, Blanco A, Maugeri N, et al: Platelet function and intraplatelet von ciated with monoclonal gammopathy: A single-center study of 36 patients. Medicine
Willebrand factor antigen and fibrinogen in myelodysplastic syndromes. Thromb Res (Baltimore) 90(6):404–411, 2011.
46(4):601–606, 1987. 372. Howard CR, Lin TL, Cunningham MT, Lipe BC: IgG kappa monoclonal gammopa-
340. Zeidman A, Sokolover N, Fradin Z, et al: Platelet function and its clinical significance thy of undetermined significance presenting as acquired type III Von Willebrand syn-
in the myelodysplastic syndromes. Hematol J 5(3):234–238, 2004. drome. Blood Coagul Fibrinolysis 25(6):631–633, 2014.
341. Bellucci S, Huisse MG, Boval B, et al: Defective collagen-induced platelet activation in 373. Coucke L, Marcelis L, Deeren D, et al: Lymphoplasmacytic lymphoma exposed by hae-
two patients with malignant haemopathies is related to a defect in the GPVI-coupled moptysis and acquired von Willebrand syndrome. Blood Coagul Fibrinolysis 25(4):395–
signalling pathway. Thromb Haemost 93(1):130–138, 2005. 397, 2014.
342. Girtovitis FI, Ntaios G, Papadopoulos A,: Defective platelet aggregation in myelodys- 374. Scepansky E, Othman M, Smith H: Acquired von Willebrand syndrome with a type 2B
plastic syndromes. Acta Haematol 118(2):117–122, 2007. phenotype: Diagnostic and therapeutic dilemmas. Acta Haematol 131(4):213–217, 2014.
343. Burbury KL, Seymour JF, Dauer R, Westerman DA: Under-recognition of platelet dys- 375. Wallace MR, Simon SR, Ershler WB, Burns SL: Hemorrhagic diathesis in multiple mye-
function in myelodysplastic syndromes: Are we only seeing the tip of the iceberg? Leuk loma. Acta Haematol 72(5):340–342, 1984.
Lymphoma 54(1):11–13, 2013. 376. Hyman BT, Westrick MA: Multiple myeloma with polyneuropathy and coagulopathy. A
344. Frigeni M, Galli M: Childhood myelodysplastic syndrome associated with an acquired case report of the polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin
Bernard-Soulier-like platelet dysfunction. Blood 124(16):2609, 2014. change (POEMS) syndrome. Arch Intern Med 146(5):993–994, 1986.
345. Pui CH, Jackson CW, Chesney C: Normal platelet function after therapy for acute lym- 377. Bovill EG, Ershler WB, Golden EA, et al: A human myeloma-produced monoclonal
phocytic leukemia. Arch Intern Med 143(1):73–74, 1983. protein directed against the active subpopulation of von Willebrand factor. Am J Clin
346. Andre JM, Galambrun C, Trzeciak MC, et al: Acquired Glanzmann’s thrombasthenia Pathol 85(1):115–123, 1986.
associated with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 27(10):554–557, 378. Silberstein LE, Abrahm J, Shattil SJ: The efficacy of intensive plasma exchange in
2005. acquired von Willebrand’s disease. Transfusion 27(3):234–237, 1987.
347. Raman V, Quillen K, Sloan JM: Acquired Glanzmann thrombasthenia associated with 379. Federici AB, Stabile F, Castaman G, et al: Treatment of acquired von Willebrand syn-
Hodgkin lymphoma: Rapid reversal of functional platelet defect with ABVD (Adriamy- drome in patients with monoclonal gammopathy of uncertain significance: Compari-
cin/bleomycin/vinblastine/dacarbazine) chemotherapy. Clin Lymphoma Myeloma Leuk son of three different therapeutic approaches. Blood 92(8):2707–2711, 1998.
14(2):e51–e54, 2014. 380. Federici AB: Use of intravenous immunoglobulin in patients with acquired von Wille-
348. Westbrook CA, Golde DW: Clinical problems in hairy cell leukemia: Diagnosis and brand syndrome. Hum Immunol 66(4):422–430, 2005.
management. Semin Oncol 11(4 Suppl 2):514–522, 1984. 381. Federici AB, Budde U, Castaman G, et al: Current diagnostic and therapeutic
349. Rosove MH, Naeim F, Harwig S, Zighelboim J: Severe platelet dysfunction in hairy cell approaches to patients with acquired von Willebrand syndrome: A 2013 update. Semin
leukemia with improvement after splenectomy. Blood 55(6):903–906, 1980. Thromb Hemost 39(2):191–201, 2013.
350. Roussi JH, Houbouyan LL, Alterescu R, et al: Acquired von Willebrand’s syndrome 382. Mazoyer E, Fain O, Dhote R, Laurian Y: Is rituximab effective in acquired von Wille-
associated with hairy cell leukaemia. Br J Haematol 46(3):503–506, 1980. brand syndrome? Br J Haematol 144(6):967–968, 2009.
351. Lackner H: Hemostatic abnormalities associated with dysproteinemias. Semin Hematol 383. Michiels JJ, Budde U, van der Planken M, et al: Acquired von Willebrand syndromes:
10(2):125–133, 1973. Clinical features, aetiology, pathophysiology, classification and management. Best Pract
352. Coppola A, Tufano A, Di Capua M, Franchini M: Bleeding and thrombosis in multiple Res Clin Haematol 14(2):401–436, 2001.
myeloma and related plasma cell disorders. Semin Thromb Hemost 37(8):929–945, 2011. 384. Kumar S, Pruthi RK, Nichols WL: Acquired von Willebrand disease. Mayo Clin Proc
353. Perkins HA, MacKenzie MR, Fudenberg HH: Hemostatic defects in dysproteinemias. 77(2):181–187, 2002.
Blood 35(5):695–707, 1970. 385. Hong S, Lee J, Chi H, et al: Systemic lupus erythematosus complicated by acquired von
354. Rapoport M, Yona R, Kaufman S, et al: Unusual bleeding manifestations of amyloidosis Willebrand’s syndrome. Lupus 17(9):846–848, 2008.
in patients with multiple myeloma. Clin Lab Haematol 16(4):349–353, 1994. 386. Pruthi RK: Hypertrophic obstructive cardiomyopathy, acquired von Willebrand syn-
355. Furie B, Greene E, Furie BC: Syndrome of acquired factor X deficiency and systemic drome, and gastrointestinal bleeding. Mayo Clin Proc 86(3):181–182, 2011.
amyloidosis in vivo studies of the metabolic fate of factor X. N Engl J Med 297(2):81–85, 387. Casonato A, Sponga S, Pontara E, et al: Von Willebrand factor abnormalities in aortic
1977. valve stenosis: Pathophysiology and impact on bleeding. Thromb Haemost 106(1):58–
356. McPherson RA, Onstad JW, Ugoretz RJ, Wolf PL: Coagulopathy in amyloidosis: Com- 66, 2011.
bined deficiency of factors IX and X. Am J Hematol 3:225–235, 1977. 388. Heilmann C, Geisen U, Beyersdorf F, et al: Acquired von Willebrand syndrome in
357. Palmer RN, Rick ME, Rick PD, Zeller JA, Gralnick HR: Circulating heparan sulfate patients with extracorporeal life support (ECLS). Intensive Care Med 38(1):62–68, 2012.
anticoagulant in a patient with a fatal bleeding disorder. N Engl J Med 310(26):1696– 389. Meyer AL, Malehsa D, Budde U, et al: Acquired von Willebrand syndrome in patients
1699, 1984. with a centrifugal or axial continuous flow left ventricular assist device. JACC Heart Fail
358. Chapman GS, George CB, Danley DL: Heparin-like anticoagulant associated with 2(2):141–145, 2014.
plasma cell myeloma. Am J Clin Pathol 83(6):764–766, 1985. 390. Morrison KA, Jorde UP, Garan AR, et al: Acquired von Willebrand disease during
359. Torjemane L, Guermazi S, Ladeb S, et al: Heparin-like anticoagulant associated with CentriMag support is associated with high prevalence of bleeding during support and
multiple myeloma and neutralized with protamine sulfate. Blood Coagul Fibrinolysis after transition to heart replacement therapy. ASAIO J 60(2):241–242, 2014.
18(3):279–281, 2007. 391. Mitrovic M, Elezovic I, Miljic P, Suvajdzic N: Acquired von Willebrand syndrome in
360. Liebman H, Chinowsky M, Valdin J, et al: Increased fibrinolysis and amyloidosis. Arch patients with Gaucher disease. Blood Cells Mol Dis 52(4):205–207, 2014.
Intern Med 143(4):678–682, 1983. 392. Federici AB: Acquired von Willebrand syndrome associated with hypothyroidism: A
361. Meyer K, Williams EC: Fibrinolysis and acquired alpha-2 plasmin inhibitor deficiency mild bleeding disorder to be further investigated. Semin Thromb Hemost 37(1):35–40,
in amyloidosis. Am J Med 79(3):394–396, 1985. 2011.

Kaushansky_chapter 121_p2073-2096.indd 2092 9/18/15 10:28 AM